Darbà, JosepAscanio, MeritxellCarvalho, DavideConde, VascoPedersen, Kasper S.2020-06-102020-12-202019-12-201646-3439https://hdl.handle.net/2445/164999Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)10 p.application/pdfengcc-by-nc-nd (c) Cortex - Publicacoes Tecnicas e Cientificas, 2019http://creativecommons.org/licenses/by-nc-nd/3.0/esAnàlisi cost-beneficiSalut públicaDiabetisInsulinaPortugalCost effectivenessPublic healthDiabetesInsulinPortugalinfo:eu-repo/semantics/article6957762020-06-10info:eu-repo/semantics/openAccess